SAS Drug Development Adds Genomic-Analysis Capabilities
Solution addresses biomarkers, incorporates molecular information
PHILADELPHIA, June 19, 2006-SAS, the leader in business intelligence, today announced new genomic-analysis capabilities for its flagship life sciences offering, SAS® Drug Development. These new capabilities will make it easier for pharmaceutical companies to analyze genetic data and incorporate this analysis into new drug applications.
SAS Drug Development is a powerful data management and analysis solution for pharmaceutical, medical device and biotechnology firms. More than 90 processes for genomic and proteomic-specific molecular analyses-powered by JMP® software-are now incorporated into SAS Drug Development, addressing the areas of:
- Genetics. For genetic marker data, case-control or pedigree experiments. Useful for characterizing genetic variability and evaluating its association with biological effects, such as disease or adverse events.
- Microarrays. For gene expression or RNA transcript abundance data. Useful for investigating gene utilization to understand disease or biological processes.
- Proteomics. For spectral data on peptides or metabolites. Useful for identifying protein biomarkers and their association with disease or traits.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
